Advertisement
Screener

Cue Biopharma, Inc. (CUE) Cash Flow Breakdown

2.8 / 5 stars · 68/120 Roast Me

Cue Biopharma, Inc. Cash Flow Breakdown

Cash flow breakdown shows where Cue Biopharma, Inc.'s cash came from and where it went: from running the business, from investing (buying or selling equipment, companies and investments) and from financing (borrowing, paying back loans, buying back shares, paying dividends). One row per year or quarter. A minus sign means cash went out. Financing is shown line by line: buybacks, dividends, debt paid back, new debt and the rest. All amounts are the filed figures for that period.

  • Fiscal year ended 2025-12-31: from running the business, $21.69M went out.
  • Fiscal year ended 2025-12-31: from investing, $75.00K came in.
  • Fiscal year ended 2025-12-31: from financing, $26.29M came in.
  • Fiscal year ended 2025-12-31: change in cash, $4.68M came in.

A minus sign means cash went out. * = worked out from the filed year-to-date figures (hover to see how); greyed = already counted inside another line.

Each year (12 month)

Fiscal year endRunning the businessFrom investingBuybacksNew debtNew shares soldNot split outChange in cash
2025-12-31-$21.69M$75.00K$28.29M-$2.00M*$4.68M
2024-12-31-$36.33M$32.00K$10.81M-$570.00K*-$26.05M
2023-12-31-$39.96M$25.00M$0.00$0.00$0.00$11.86M*-$3.10M
2022-12-31-$41.81M-$24.61M-$200.00K$10.00M$22.70M$21.16M*-$12.76M
2021-12-31-$38.84M$9.11M-$750.13K$0.00$0.00$19.98M*-$10.50M
2020-12-31-$32.49M$4.46M-$271.05K$56.68M$2.20M*$30.58M
2019-12-31-$30.80M$3.45M-$91.03K$49.00M$1.88M*$23.44M
2018-12-31-$26.41M-$20.35M$12.50K$4.17M*-$42.58M
2017-12-31-$12.14M-$1.20M$8.01K$62.00M*$48.66M

Each quarter (3 month)

Quarter endRunning the businessFrom investingBuybacksDebt paid backNew debtNew shares soldNot split outChange in cash
2026-06-30-$29.00M*$0.00*$30.02M*
2026-03-31-$10.94M-$121.00K-$10.76M
2025-12-31-$1.08M*$7.02M*$10.24M*-$751.00K*
2025-09-30-$9.02M*-$6.77M*$0.00*
2025-06-30-$3.42M*-$27.00K*$17.80M*
2025-03-31-$8.17M-$150.00K-$100.00K-$900.00K*-$9.32M
2024-12-31-$9.03M*-$1.00K*-$8.00K*-$924.00K*
2024-09-30-$7.53M*$98.00K*-$100.00K$10.82M*-$900.00K*
2024-06-30-$9.99M*-$10.00K*-$33.00K$0.00*-$967.00K*
2024-03-31-$9.78M-$55.00K-$100.00K$0.00$2.45M*-$7.49M
2023-12-31-$10.96M*$0.00*$0.00*$0.00*$0.00*$4.78M*
2023-09-30-$7.80M*$5.00M*$0.00*-$33.00K$0.00*$0.00*$4.62M*
2023-06-30-$10.37M*$5.00M*$0.00*-$33.00K$0.00*$85.00K*$2.05M*
2023-03-31-$10.83M$15.00M$0.00$0.00$388.00K$4.56M
2022-12-31-$10.51M*$5.00M*$0.00*$0.00*$0.00*$27.40M*
2022-09-30-$6.87M*-$29.52M*-$9.00K*$0.00*$0.00*
2022-06-30-$12.85M*-$62.00K*$0.00*$0.00*$0.00*$11.11M*
2022-03-31-$11.57M-$27.00K-$191.00K$10.00M$0.00$5.35M*$3.56M
2021-12-31-$10.65M*$511.00*-$183.13K*$0.00*$537.78K*$7.03M*
2021-09-30-$6.63M*-$11.00K*-$482.00K*$0.00*$833.00K*
2021-06-30-$9.77M*-$233.00K*$0.00*$309.00K*$10.36M*
2021-03-31-$11.79M$9.35M-$85.00K$919.00K-$1.61M
2020-12-31-$7.00M*$9.89M*-$160.05K*$236.00*
2020-09-30-$7.69M*$4.65M*-$35.00K*$14.33M*$719.00K*
2020-06-30-$6.86M*-$140.00K*$1.04M*$42.28M*
2020-03-31-$10.94M-$9.95M$36.00K-$20.86M
2019-12-31-$6.44M*-$15.15M*$33.35M*$1.15M*
2019-09-30-$9.21M*$3.98M*$11.94M*
2019-06-30-$6.68M*$5.13M*$32.00K*$3.71M*
2019-03-31-$8.47M$9.48M$257.00K$1.26M
2018-12-31-$3.90M*$4.69M*$500.00*$4.17M*
2018-09-30-$6.30M*-$23.61M*
2018-06-30-$6.46M*-$760.00K*
2018-03-31-$9.76M-$673.00K-$10.43M
2017-12-31-$1.85M*-$18.98K*$62.05M*
2017-09-30-$3.68M*-$208.00K*
2017-03-31-$3.46M-$556.00K-$4.02M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73
MACROGENICS INC (MGNX)United States$0.242B-20.11
Pyxis Oncology, Inc. (PYXS)United States$0.244B
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
Lyell Immunopharma, Inc. (LYEL)United States$0.248B-1.32
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33
Cartesian Therapeutics, Inc. (RNAC)United States$0.231B-2.04
Akebia Therapeutics, Inc. (AKBA)United States$0.255B-10.35
Keros Therapeutics, Inc. (KROS)United States$0.229B-2.55